Regulatory compliance – Page 32

Test article accountability issue during routine studies – inspection deficiency risk analysis

Managing Test Article Accountability During Routine Studies to Mitigate Inspection Deficiencies The integrity of test article accountability in routine studies is paramount in upholding Good Laboratory Practices (GLP) compliance. Even…

ERES controls not implemented during system operation – preventing repeat Part 11 findings

Implementing Effective Controls to Prevent ERES System Operation Failures The increasing reliance on electronic records and electronic signatures (ERES) in the pharmaceutical industry underscores the importance of robust controls. ERES…

Requalification overdue during inspection readiness – inspection evidence expectations

Addressing Requalification Gaps Ahead of Inspections: Evidence Expectations and Remediation Strategies The pharmaceutical manufacturing landscape requires strict adherence to regulatory guidelines, specifically during inspections where requalification of equipment and processes…

ERES controls not implemented during system upgrade – risk-based ERES remediation

Risk-Based Remediation for Inadequate ERES Controls During System Upgrade In the rapidly evolving landscape of pharmaceutical compliance, the implementation of Electronic Records and Electronic Signatures (ERES) controls during system upgrades…

Change impact not assessed during lifecycle management – inspection evidence expectations

Understanding Change Impact During Lifecycle Management: Ensuring Compliance and Readiness for Inspections The pharmaceutical industry operates under stringent regulations and guidelines that require rigorous adherence to quality and compliance measures.…

Hybrid paper-electronic workflows uncontrolled during validation lifecycle – 21 CFR Part 11 compliance gaps

Managing Uncontrolled Hybrid Paper-Electronic Workflows During Validation Lifecycle As digital transformation accelerates within pharmaceutical manufacturing, uncontrolled hybrid paper-electronic workflows pose significant regulatory compliance risks, particularly concerning 21 CFR Part 11.…

CSV compliance weak during site expansion – regulatory deficiency risk

Managing Weak CSV Compliance During Site Expansion: A Playbook for Pharma Professionals Expanding pharmaceutical manufacturing operations poses significant challenges in computer system validation (CSV), often leading to risks of regulatory…

Deviation handling weak during sponsor oversight – preventing repeat GLP findings

Strategies to Enhance Deviation Handling During Sponsor Oversight and Prevent GLP Findings In the realm of pharmaceutical manufacturing and laboratory practices, the complexity of regulated environments can often lead to…

Electronic signatures misused during inspection walkthrough – CAPA and revalidation strategy

Mitigating Misuse of Electronic Signatures During Inspection Walkthroughs: A Comprehensive Playbook The increasing reliance on electronic signatures in the pharmaceutical sector brings both efficiency and regulatory challenges, particularly during inspection…

Inadequate worst-case selection during inspection readiness – CAPA and revalidation strategy

Improving Worst-Case Selection for Enhanced Inspection Readiness In the highly regulated pharmaceutical industry, inadequate worst-case selection during inspection preparation can lead to significant compliance issues. As a professional engaged in…

Record retention failures during system operation – risk-based ERES remediation

Addressing Record Retention Failures during System Operations – A Comprehensive Playbook Record retention failures during system operation pose significant risks to data integrity and compliance within the pharmaceutical industry. These…

Incomplete validation lifecycle during inspection readiness – regulatory deficiency risk

Managing Incomplete Validation Lifecycle During Inspection Readiness to Mitigate Regulatory Deficiency Risks In a highly regulated pharmaceutical environment, maintaining a complete validation lifecycle is crucial for ensuring compliance and avoiding…